Pharmacist substitution of biological products: Issues and considerations

Journal of Managed Care Pharmacy

Volumn 21, Issue 7, 2015, Pages 532-539

  Li, Edward ^a   Ramanan, Sundar ^b   Green, Larry ^b  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; DRUG; GENERIC DRUG; SMALL MOLECULE DRUG; UNCLASSIFIED DRUG;

ARTICLE; DRUG APPROVAL; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; MANAGED CARE; PHARMACIST; PHARMACY; PROFESSIONAL PRACTICE; UNITED STATES; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG SUBSTITUTION; DRUGS, GENERIC; HUMANS; PHARMACEUTICAL SERVICES; PHARMACISTS; PROFESSIONAL ROLE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84934767258     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.7.532     Document Type: Article

References (30)

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. April 2015. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM291128.pdf. Accessed June 1, 2015.
2. European Medicines Agency. Omnitrope (somatropin). Authorisation details. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000607/human_med_000946.jsp&mid= WC0b01ac058001d124. Accessed June 1, 2015..
3. Genazzani AA, Biggio G, Caputi AP, et al. Biosimilar drugs: concerns and opportunities. BioDrugs. 2007;21(6):351-56.
4. Prugnaud JL. Similarity of biotechnology-derived medicinal products:specific problems and new regulatory framework. Br J Clin Pharmacol.2008;65(4):619-20. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2291378/. Accessed June 1, 2015.
5. Crommelin DJ, Storm G, Verrijk R, de Leede L, Jiskoot W, Hennink WE. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs.Int J Pharm.2003;266(1-2):3-16.
6. Gottlieb S. Biosimilars: policy, clinical, and regulatory considerations.Am J Health Syst Pharm.2008;65(14 Suppl 6):S2-S8
7. Roger SD. Biosimilars: How similar or dissimilar are they? Nephrology (Carlton).2006;11(4):341-46.
8. Federal Food, Drug, and Cosmetic Act. 21 U.S.C., chapter 9. Available at:http://www.fda.gov/RegulatoryInformation/Legislation/Federal FoodDrugandCosmeticActFDCAct/default.htm. Accessed June 1, 2015.
9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Revision March 1, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFIBioAvail-BioEquiv.pdf. Accessed June 1, 2015.
10. Public Health Service Act. 42 U.S.C., chapter 6A. Available at: http:// www.fda.gov/RegulatoryInformation/Legislation/ucm148717.htm. Accessed June 1, 2015.
11. Biologics Price Competition and Innovation Act. Public Law 111-148, section 7001-7003. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Accessed June 1, 2015.
12. Patient Protection and Affordable Care Act. Public Law 111-148. Available at: http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf. Accessed June 1, 2015.
13. Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: implications for health-system pharmacists. Am J Health Syst Pharm. 2013;70(22):2004-17.
14. Tyler LS, Cole SW, May JR, et al. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health Syst Pharm.2008;65(13):1272-83.
15. Abood, RR. Pharmacy Practice and the Law. 6th ed. Sudbury, MA: Jones & Bartlett Publishers; 2010.
16. U.S. Food and Drug Administration. Orange Book preface. Available at:http://www.fda.gov/drugs/developmentapprovalprocess/ucm079068.htm. Accessed June 1, 2015.
17. State regulations on generic substitution. Pharmacist's Letter/Prescriber's Letter. 2006;22(9):220901. Available at: http://pharmacistsletter.therapeuticresearch. com/pl/ArticlePDF.aspx?dd=220901&segment=1186. Accessed June 1, 2015.
18. Vivian JC. Generic-substitution laws. US Pharm. 2008;33(6):30-34.
19. National Association of Boards of Pharmacy. Generic drug substitution requires pharmacist attention to ensure compliance with state laws and regulations. National Association of Boards of Pharmacy Newsletter.2013;42(6):135-36,140. Available at: http://www.nabp.net/system/redactor_ assets/documents/618/Final_June-July_2013_Newsletter.pdf. Accessed June 15, 2015.
20. U.S. Food and Drug Administration. Code of Federal Regulations, Title 21 Section 320.33(c). Available at: http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.33. Accessed June 1, 2015.
21. U.S. Federal Trade Commission, Bureau of Consumer Protection. Drug Product Selection: Staff Report to the Federal Trade Commission.Ann Arbor, MI:University of Michigan Library; 1979.
22. Kozlowski S, Woodcock J, Midthun K, Behrman Sherman RB. Developing the nation's biosimilars program. N Engl J Med.2011;365(5):385-88. Available at: http://www.nejm.org/doi/full/10.1056/NEJMp1107285. Accessed June 1, 2015.
23. U.S. Food and Drug Administration, Center for Drug Evauation Research. List of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. Available at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ UCM411909.pdf. Accessed June 1, 2015.
24. Biotechnology Industry Organization. BIO principles on patient safety in the substitution of biologic products. January 24, 2013. Available at: http:// www.bio.org/advocacy/letters/bio-principles-patient-safety-substitutionbiologic- products. Accessed June 1, 2015.
25. Academy of Managed Care Pharmacy. Where we stand: biosimilar drug therapies. April 2012. Available at: http://www.amcp.org/WorkArea/ DownloadAsset.aspx?id=18693. Accessed June 15, 2015.
26. American Pharmacists Association, National Association of Chain Drug Stores, National Community Pharmacists Association. Letter to U.S. Food and Drug Administration, Division of Dockets Management (HFA-305). May 25, 2012. Available at: http://www.ncpanet.org/pdf/leg/may12/joint_biosimilar_ letter.pdf. Accessed June 1, 2015.
27. European Commission. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, directive 2001/83/EC on the Community code relating to medicinal products for human use. 2010 OJ L348/74. Available at: http:// ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf. Accessed June 1, 2015.
28. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.Blood. 1993;81(8):2180-86. Available at: http://www.bloodjournal.org/content/81/8/2180.long. Accessed June 1, 2015.
29. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80(1):88-92.
30. Wieser C, Rosenkranz AR. Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin Kidney J.2013;6(5):539-42.